Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (TCM) whereas ex viv...
Saved in:
Main Authors: | Lawrence G Lum, Parameswaran Hari, Aniko Szabo, Michele Donato, Jee Hyun Park, Daniel H Fowler, Binod Dhakal, Saurabh Chhabra, Deborah D Glass, David S Siegel, Tania C Felizardo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e010649.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Microwave Pioneers: Mau-Chung Frank Chang, “The Power of Connections”
by: Peter H. Siegel
Published: (2025-01-01) -
99m Tc-MIBI 与201T1 肺肿瘤阳性显像 在原发性肺癌的比较
by: 岳殿超, et al.
Published: (2000-01-01) -
Pieris Rapae in Mid-ocean
by: Samuel H. Scudder
Published: (1876-01-01) -
Protocol for microinjection of rapamycin into the zebrafish habenula
by: Olga Doszyn, et al.
Published: (2025-03-01) -
Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
by: Oana Hangiu, et al.
Published: (2025-01-01)